Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 3, 2010, Pages 332-339

  Cavender, Matthew A ^a   Rao, Sunil V ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndrome; Anti coagulation agents; Anti platelet agents; Coagulation; Hemorrhage; Platelet aggregation

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CANGRELOR; CLOPIDOGREL; DABIGATRAN; DALTEPARIN; E 5555; ELINOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; M 118; MELAGATRAN; PLACEBO; PRASUGREL; PRT 060128; TERUTROBAN; THROMBIN; THROMBOXANE A2; TICAGRELOR; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; AGING; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; EVIDENCE BASED MEDICINE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INTESTINAL BLEEDING; INTRAOCULAR HEMORRHAGE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSITIVE FEEDBACK; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 77957959905     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0487-z     Document Type: Review

References (44)

1. Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)
2. Anderson JL et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50(7):e1-e157
3. SC Smith Jr 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 10 2130 2139 10.1016/j.jacc.2006.04.026 16697342 (Pubitemid 44275145)
4. MA Cavender SV Rao EM Ohman 2008 Major bleeding: management and risk reduction in acute coronary syndromes Expert Opin Pharmacother 9 11 1869 1883 1:CAS:528:DC%2BD1cXos1Cgsr4%3D 10.1517/14656566.9.11.1869 18627326
5. Fauci AS (2008) Harrison's principles of internal medicine, 17th edn. McGraw-Hill Medical, New York, 2 vols, xxxvii, 2754 p, 149 p
6. Guyton AC, Hall JE (2006) Textbook of medical physiology, 11th edn. Elsevier Saunders, Philadelphia, xxxv, 1116 p
7. MP Abbracchio, et al. 2006 International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy Pharmacol Rev 58 3 281 341 1:CAS:528:DC%2BD28XhtVOhtLbF 10.1124/pr.58.3.3 16968944 (Pubitemid 44394905)
8. KG Mann 2003 Thrombin formation Chest 124 3 Suppl 4S 10S 1:CAS:528:DC%2BD3sXotVensL0%3D 10.1378/chest.124.3-suppl.4S 12970118
9. SR Coughlin 2005 Protease-activated receptors in hemostasis, thrombosis and vascular biology J Thromb Haemost 3 8 1800 1814 1:CAS:528: DC%2BD2MXpsFKjs7w%3D 10.1111/j.1538-7836.2005.01377.x 16102047 (Pubitemid 41716567)
10. M Moscucci, et al. 2003 Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 20 1815 1823 1:STN:280:DC%2BD3svosFemsw%3D%3D 10.1016/S0195-668X(03)00485-8 14563340 (Pubitemid 37280247)
11. JW Eikelboom, et al. 2006 Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 8 774 782 10.1161/CIRCULATIONAHA.106.612812 16908769 (Pubitemid 44268228)
12. X Yang, et al. 2005 The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative J Am Coll Cardiol 46 8 1490 1495 10.1016/j.jacc.2005.06.072 16226173 (Pubitemid 41446184)
13. F Feit, et al. 2007 Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial Am J Cardiol 100 9 1364 1369 10.1016/j.amjcard.2007.06.026 17950791 (Pubitemid 47576015)
14. TD Kinnaird, et al. 2003 Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions Am J Cardiol 92 8 930 935 10.1016/S0002-9149(03)00972-X 14556868 (Pubitemid 37214804)
15. AJ Kirtane, et al. 2006 Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol 47 12 2374 2379 1:CAS:528:DC%2BD28Xls1artr0%3D 10.1016/j.jacc.2005.09.080 16781361 (Pubitemid 43866383)
16. S Subherwal, et al. 2009 Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score Circulation 119 14 1873 1882 10.1161/CIRCULATIONAHA.108.828541 19332461
17. SS Anand, et al. 2003 Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin Circulation 107 23 2884 2888 10.1161/01.CIR.0000077530. 53367.E9 12796128 (Pubitemid 36736627)
18. JJ Ferguson, et al. 2004 Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 1 45 54 1:CAS:528:DC%2BD2cXls1elsrg%3D 10.1001/jama.292.1.45 15238590 (Pubitemid 38923793)
19. GW Stone, et al. 2006 Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 21 2203 2216 1:CAS:528:DC%2BD28Xht1Chsb3L 10.1056/NEJMoa062437 17124018 (Pubitemid 44791162)
20. GW Stone, et al. 2008 Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 21 2218 2230 1:CAS:528:DC%2BD1cXmt1Gju7Y%3D 10.1056/NEJMoa0708191 18499566 (Pubitemid 351724451)
21. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2(8607):349-360 (1988)
22. FG Kushner, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 54 23 2205 2241 10.1016/j.jacc.2009.10.015 19942100
23. S Yusuf, et al. 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 7 494 502 1:CAS:528:DC%2BD3MXms1arsrY%3D 10.1056/NEJMoa010746 11519503 (Pubitemid 32758501)
24. KA Fox, et al. 2004 Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial Circulation 110 10 1202 1208 1:CAS:528:DC%2BD2cXntFSksL8%3D 10.1161/01.CIR.0000140675.85342.1B 15313956 (Pubitemid 39202333)
25. DL Bhatt 2007 Intensifying platelet inhibition-navigating between Scylla and Charybdis N Engl J Med 357 20 2078 2081 1:CAS:528:DC%2BD2sXhtlWis7vK 10.1056/NEJMe0706859 17982183 (Pubitemid 350106717)
26. SD Wiviott, et al. 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 20 2001 2015 1:CAS:528: DC%2BD2sXhtlWis7rN 10.1056/NEJMoa0706482 17982182 (Pubitemid 350106708)
27. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247):2037-2044 (2000)
28. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339(7):436-443 (1998)
29. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71-86 (2002)
30. S Derry YK Loke 2000 Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis BMJ 321 7270 1183 1187 1:CAS:528: DC%2BD3cXovVeltL8%3D 10.1136/bmj.321.7270.1183 11073508
31. RJ Peters, et al. 2003 Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Circulation 108 14 1682 1687 1:CAS:528:DC%2BD3sXns1Cgu78%3D 10.1161/01.CIR.0000091201.39590.CB 14504182 (Pubitemid 37243654)
32. SV Rao, et al. 2007 Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur Heart J 28 10 1193 1204 10.1093/eurheartj/ehm019 17456480 (Pubitemid 47343833)
33. SV Rao, et al. 2005 Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes Am J Cardiol 96 9 1200 1206 10.1016/j.amjcard.2005.06.056 16253582 (Pubitemid 41505393)
34. TR Tolleson, et al. 2003 Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial J Am Coll Cardiol 41 3 386 393 1:CAS:528:DC%2BD3sXhvFCitLs%3D 10.1016/S0735-1097(02)02767-5 12575964 (Pubitemid 36164491)
35. MR Lassen, et al. 2002 Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison Lancet 359 9319 1715 1720 1:CAS:528:DC%2BD38XktFKjsbc%3D 10.1016/S0140-6736(02)08652-X 12049858 (Pubitemid 34607083)
36. S Yusuf, et al. 2006 Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 14 1464 1476 1:CAS:528:DC%2BD28XjtFWhuro%3D 10.1056/NEJMoa055443 16537663
37. Budaj A et al (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30(6):655-661
38. KP Alexander, et al. 2005 Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes JAMA 294 24 3108 3116 1:CAS:528:DC%2BD28Xmtl2l 10.1001/jama.294.24.3108 16380591 (Pubitemid 43016802)
39. NM LaPointe, et al. 2007 Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes Arch Intern Med 167 14 1539 1544 1:CAS:528: DC%2BD2sXpt1Gmsbg%3D 10.1001/archinte.167.14.1539 17646609 (Pubitemid 47124185)
40. TY Wang, et al. 2008 Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding Circulation 118 21 2139 2145 1:CAS:528:DC%2BD1cXhtlGls73L 10.1161/CIRCULATIONAHA.108.787143 18981304
41. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 9 1038 1047 1:CAS:528:DC%2BD28XlsFGqtLs%3D 10.1093/eurheartj/ehi754 16476694
42. 12 antagonism: promises and challenges Arterioscler Thromb Vasc Biol 28 3 s33 s38 1:CAS:528:DC%2BD1cXit1Oltrs%3D 10.1161/ATVBAHA.107.160689 18174449
43. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 151(3):689e1-689e10
44. RC Becker, et al. 2009 Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Lancet 373 9667 919 928 1:CAS:528:DC%2BD1MXjtFKqtrs%3D 10.1016/S0140-6736(09)60230-0 19286091